glp 1 and restless leg syndrome A Closer Look at the Dermatological Profile of GLP-1 Agonists Restless Legs syndrome (RLS): Paddy

Microdosing GLP-1 lacks clinical trial evidence and regulatory approval, making its safety profile unknown

Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article

Lovshin, J., Estall, J., Yusta, B., Brown, T

weight loss by people not meeting guidelines), and safety/ethical issues, especially in direct-to-consumer contexts

This review has deliberately distinguished failed biology from failed pharmacology, emphasizing that genuine on-target toxicity, repeated lack of efficacy in well-designed human studies, or insurmountable technical barriers justify abandonment

Meds to lose the weight